ACTICOR BIOTECH: Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023
27 April 2023 - 4:00AM
Business Wire
Regulatory News:
ACTICOR BIOTECH (Paris:ALACT) (FR0014005OJ5 - ALACT), a
clinical-stage biotechnology company focused on the development of
innovative drugs for the treatment of cardiovascular emergencies,
in particular stroke, announces today the availability of its
Universal Registration Document for the fiscal year ending December
31, 2022, as well as the preparatory documents for its Combined
General Meeting on May 12, 2023.
Availability of the 2022 Universal Registration
Document
The Universal Registration Document 2022, filed with the French
stock-market authority (Autorité des Marchés Financiers) on April
26, 2023 under visa number R. 23-020, is available free of charge
to the public under the conditions provided for by the regulations
in force and can be consulted on the Company's website (Investors /
Regulated Information / Financial Information / 2023), as well as
on the AMF website (www.amf-france.org).
This Universal Registration Document includes in particular the
annual financial report, the management report, the corporate
governance report, the information relating to the fees paid to the
statutory auditors and the reports of the Statutory Auditors.
Availability of the documents relating to the General
Meeting
The combined general meeting of the Company will be held on
Friday May 12, 2023 at 9:00 a.m. at the Acticor Biotech
headquarters located at the Wojo Building, 82 avenue du Maine,
75014 Paris, room on the 7th floor
The notice of meeting as notice of convocation, including the
agenda and the draft resolutions as well as the conditions and
modalities of participation and voting at the meeting, has been
posted on the website of the Bulletin des Annonces légales
Obligatoires "BALO" (www.journal-officiel.gouv.fr/balo) on April 5,
2023, bulletin number 41. The notice of meeting is published on the
website in legal announcements “Actu-Juridique”
(http://www.actu-juridique.fr) on April 24, 2023.
If shareholders are unable to attend the meeting in person,
shareholders may exercise their voting rights remotely, before the
meeting:
- either by sending a proxy to the Company
- or by voting by mail,
by using the voting form available on
https://fr.acticor-biotech.com/ in accordance with the procedures
indicated in the prior notice published in the BALO on April 5,
2023.
The preparatory documents relating to this general meeting are
available on request from the Company, or can be consulted on the
company's website in the Investors section. In accordance with
applicable legal and regulatory provisions:
- Any registered shareholder may, up to and including the fifth
day before the General Meeting, request the Company to send him the
documents provided for in Articles L. 225-115 and R. 225-83 of the
French Commercial Code. In the event of an express request, the
documents may be sent by electronic means. For holders of bearer
shares, the exercise of this right is subject to the provision by
their authorized intermediary of a certificate of account
registration;
- Any shareholder may consult the documents referred to in
Articles L. 225-115 and R. 225-83 of the French Commercial Code at
the company's registered office.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
In May 2022, Acticor Biotech presented positive results from its
Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety
profile and showing a reduction in mortality and intracerebral
hemorrhage in the glenzocimab-treated group in patients with
stroke. The efficacy of glenzocimab is now being evaluated in an
international Phase 2/3 study, ACTISAVE, which will include 1,000
patients. In July 2022, Acticor Biotech was granted "PRIME" status
by the European Medicines Agency (EMA) for glenzocimab in the
treatment of stroke. This designation will allow the company to
strengthen its interactions and obtain early dialogues with
regulatory authorities.
Acticor Biotech is supported by a panel of European and
international investors (Karista, Go Capital, Newton Biocapital,
CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited,
Mirae Asset Capital, Anaxago, Mediolanum farmaceutici and the
Armesa foundation). Acticor Biotech is listed on Euronext Growth
Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005841/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13 Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38 13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95 NewCap Arthur
ROUILLÉ Media Relations acticor@newcap.eu T. : +33 (0)1 44 71 00
15
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Apr 2024 to May 2024
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From May 2023 to May 2024